Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 2/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.37 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.37 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.37 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.37 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.37 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.37 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.37 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.37 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | MDM4 | O15151 | 1/20 | 0.37 |
| ▸ | MITF | O75030 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5745351 | 0.89 | KDR (0.40) | KDRHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL5746213 | 0.87 | SMN1; SMN2 (0.39) | KDRHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL5746260 | 0.83 | MDM4 (0.44) | KDRSMN1; SMN2ALDH1A1MDM4MITF | |
| SCHEMBL6958954 | 0.78 | KDR (0.47) | KDRHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL5743141 | 0.77 | KDR (0.46) | KDRHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL5746185 | 0.75 | MAPT (0.45) | KDRSMN1; SMN2ALDH1A1HTTLMNA | |
| SCHEMBL4484518 | 0.75 | RXFP1 (0.57) | SMN1; SMN2ALDH1A1TP53RAB9ANPC1 | |
| SCHEMBL5743089 | 0.74 | KDR (0.42) | KDRSMN1; SMN2ALDH1A1HTTTP53 | |
| SCHEMBL985376 | 0.71 | TP53 (0.46) | KDRTP53MAPTHPGDMEN1 | |
| SCHEMBL986276 | 0.71 | TP53 (0.46) | SMN1; SMN2TP53RAB9ANPC1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1495024-B1 | DIPYRIDODIAZEPINONES AS REVERSE TRANSCRIPTASE INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2009-01-28 | — | — | EP | disclosed |
| CN-1318420-C | Dipyridodiazepinones as reverse transcriptase inhibitors | BOEHRINGER INGELHEIM CA LTD (DE) | 2007-05-30 | — | — | CN | disclosed |
| EP-1655300-A1 | Non-nucleoside reverse transcriptase inhibitors | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2006-05-10 | — | — | EP | disclosed |
| EP-1294720-B1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | BOEHRINGER INGELHEIM CA LTD (CA) | 2006-04-05 | — | — | EP | disclosed |
| CN-1642956-A | Bipyridinodiazepine * ketone reverse transcriptase inhibitors | BOEHRINGER INGELHEIM CA LTD (DE) | 2005-07-20 | — | — | CN | disclosed |
| CN-1178939-C | Non-nucleoside reverse transcriptase inhibitors | ���ָ����Ӣ��ķ���ô�����˾ | 2004-12-08 | — | — | CN | disclosed |
| US-6706706-B2 | FOR PREVENTING PERINATAL TRANSMISSION OF HIV-1 FROM MOTHER TO BABY AND TREATING HIV INFECTION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2004-03-16 | — | — | US | disclosed |
| US-20030195197-A1 | Non-nucleoside reverse transcriptase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2003-10-16 | — | — | US | disclosed |
| CN-1436189-A | Non-nucleoside reverse transcriptase inhibitors | BOEHRINGER INGELHEIM CA LTD (CA) | 2003-08-13 | — | — | CN | disclosed |
| EP-1294720-A1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2003-03-26 | — | — | EP | disclosed |
| US-6420359-B1 | 5,11-Dihydro-11-ethyl-5-methyl-8-(2-((1-oxido-4-quinolinyl)oxy)ethyl)-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one for example; antiviral agents for HIV infection | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2002-07-16 | — | — | US | disclosed |
| US-20020028807-A1 | Non-nucleoside reverse transcriptase inhibitors | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2002-03-07 | — | — | US | disclosed |
| WO-2001096338-A1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2001-12-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030195197-A1 | Non-nucleoside reverse transcriptase inhibitors | RCOR1, POLR2H, CCR4 | KDR 4272/4885HDAC3 288/4885HDAC4 191/4885 |
| US-20020028807-A1 | Non-nucleoside reverse transcriptase inhibitors | REV1, POLR2H, POLR2E | KDR 4500/4885HDAC3 1858/4885HDAC4 1407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.